期刊文献+

HCV NS3/4A丝氨酸蛋白酶在大肠杆菌中表达、纯化 被引量:2

Expression and Purification of HCVNS3/4A Protease in the E.coli
下载PDF
导出
摘要 在大肠杆菌中HCV NS3/4A丝氨酸蛋白酶获得表达并进行纯化。根据NS3与NS4A两者形成异源二聚体的结构要求,并参照文献,通过基因拼接的方法设计了单链NS3/4A丝氨酸蛋白酶的基因。合成相应引物,利用反转录PCR从HCV患者血液中扩增出该蛋白酶的编码基因,克隆入原核表达载体pRSET-A,将重组表达质粒pRSET-A-ns3/4a转化BL211(DE3)大肠杆菌,并诱导表达与纯化。成功地构建了重组表达质粒pRSET-A-ns3/4a;重组质粒转化的BL21工程菌经IPTG诱导表达后,表达产物经SDS-PAGE和Western-blot证实为NS3/4A丝氨酸蛋白酶,并用镍离子亲和层析方法获得纯化蛋白酶。获得的纯化NS3/4A丝氨酸蛋白酶为建立其酶活性测定系统奠定了基础。 In order to expression and purify HCVNS3/4A protease in the E. coll. methods, on the basis of NS3/ 4A protease required for heterogenous dimer, the single chain NS3 and NS4A gene fused by the linker was constructed. The HCV NS3/4A gene was amplified by RT-PCR from the HCV positive serum. This fragment digested by BamH I / Hindm was cloned into pRSET-A by T4 ligase and transformed into E. coli. BL21 (DE3) ,then the recombinant plasmid named pRSET-A-ns3/4a was constructed successfully. The results show that the recombinant NS3/4A protease was expressed in the transformants distinctly after inducing by IPTG . The product was identified as NS3/4A protease by SD-PAGE and western-blot analysis . The expression production was purified on Ni^2+ -NTA column . The purified NS3/4A protease could further be used to develop the enzymatic assay.
出处 《科学技术与工程》 2008年第5期1151-1155,共5页 Science Technology and Engineering
基金 陕西省自然科学基金(2004 C2-45) 国家自然科学基金(30600564)资助
关键词 丙型肝炎病毒 NS3/4A丝氨酸蛋白酶 大肠杆菌 蛋白表达 hepatitis C virus ns3/4a protease gene E. coli protein expression
  • 相关文献

参考文献7

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2[2]Hugle T,Cerny A.Current therapy and now molecular approaches to antiviral treatment and prevention of hepatitis C.Bey Med Virol,2003;(13):361-371
  • 3[3]Lamarre D,Anderson P C,Bailey M,et al.An NS3 protease inhibitor with antiviral effects in humans.infected viith hepatitis C virus.Nature,2003;(426):186-189
  • 4[4]Li K,Foy E,Ferreon J C,et al.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.Proc Nail Aead Sci U S A,2005;102(8):2992-2997
  • 5[5]Satoh S,Tanji Y,Hijikata M,et al.The N-terminal region of hepatitis C wirus nonstructural protein 3(NS3)is essential for stable complex formation with NS4 A.J Viral,1995;69(7):4255-4260
  • 6[6]Kim J L,Morgenstern K A,Lin C,et al.Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.Cell,1996;87(2):343-355
  • 7[7]Sambrook J,Fritsh E F,Maniatis T.Molecular cloning:A laboratory manual.second edition.New York,Cold Spring Harbor;1989

二级参考文献15

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献734

同被引文献12

  • 1雷迎峰,尹文,薛小平,杨敬,吕欣,韦三华,胡兴斌,孙梦宁,徐志凯.稳定表达丙型肝炎病毒单链丝氨酸蛋白酶的HepG2细胞克隆的建立[J].第四军医大学学报,2006,27(1):42-45. 被引量:1
  • 2杨敬,薛小平,尹文,雷迎峰,吕欣,韦三华,胡兴斌,孙梦宁,徐志凯.HCV NS3蛋白单克隆抗体的制备及其识别区域的分析[J].免疫学杂志,2006,22(4):402-405. 被引量:3
  • 3Tang D C, DeVit M, Johnston S A. Genetic immunization is a simple method for eliciting an immune response [ J]. Nature, 1992, 356 (6365) :152-154.
  • 4Frelin L, Alheim M, Chen A, et al. Low dose and gene gun im- munization with a hepatitis C virus nonstructural ( NS ) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo[J]. Gene Ther, 2003, 10(8) :686-699.
  • 5Fournillier A, Nakano I, Vitvitski L, et al. Modulation of immune responses to hepatitis C virus envelope E2 protein following injec- tion of plasmid DNA using single or combined delivery mutes [ J ]. Hepatology, 1998,28 ( 1 ) :237-244.
  • 6Li K, Foy E, Ferreou J C, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF[J]. Proc Natl Acad Sci U S A,2005, 102 (8) :2992-2997.
  • 7Lang K A, Yan J, Draghia-Akli R, et al. Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype la/lb consensus DNA vaccine[J]. Vaccine, 2008, 26(49) :6225-6231.
  • 8Fytili P, Dalekos G N, Schlaphof V, et al. Cross-genotype-re- activity of the immune-dominant ttCV CD8 T-cell epitope NS3- 1073[J]. Vaccine. 2008, 26(31) :3818-3826.
  • 9Fehquatc D M, Heaney S, Webster R G, et al. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization [ J ]. J Immunol, 1997, 158 (5) : 2278 -2284.
  • 10马际尧,张亮,阎瑾琦,高江平,贾锐,王浩,刘宁,韩刚,董金凯,田仁礼,于继云.基因枪介导pVAX1-2PFcGB融合肿瘤抗原基因疫苗小鼠体内抑瘤活性研究[J].军医进修学院学报,2008,29(3):178-180. 被引量:2

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部